Based on this analysis" We believe that BLUE has established the broadest clinical proof-of-concept in the gene therapy space, with its proprietary lentivirus vector platform
and phase 1/2 program in beta-thalassemia and phase 2/3 program in childhood cerebral adrenoleukodystrophy. With full economics retained for its key lead programs, we believe that benefit in transfusion independence seen in beta-thalassemia could translate into a $1.2 billion commercial opportunity following pivotal data and that benefit in stabilization of disease progression in CCALD, while representing a smaller $280 million peak opportunity, provides additional validation for its gene therapy platform.”501 Canal Street, please take note.
In other BLUE news insider Mitchell H. Finer sold 15,000 shares of the company’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $126.03, for a total value of $1,890,450.00.
No comments:
Post a Comment